Literature DB >> 22495946

Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.

Anu Jacob1, Samira Saadoun, Joanna Kitley, Maria Leite, Jacqueline Palace, Frederick Schon, Marios C Papadopoulos.   

Abstract

In a recent study, administration of granulocyte colony stimulating factor (G-CSF) increased neuromyelitis optica (NMO) lesions in mice. Here we report a patient whose first episode of NMO may have been exacerbated by inadvertent administration of G-CSF. Histological examination of brain and spinal cord samples from three other NMO patients revealed markedly increased expression of G-CSF in neurons located in and around the lesions, with little or no expression in multiple sclerosis lesions or normal white matter. Taken together, these cases support a detrimental role for G-CSF in NMO pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495946     DOI: 10.1177/1352458512443994

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  20 in total

Review 1.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

2.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

3.  Deficiency of Socs3 leads to brain-targeted EAE via enhanced neutrophil activation and ROS production.

Authors:  Zhaoqi Yan; Wei Yang; Luke Parkitny; Sara A Gibson; Kevin S Lee; Forrest Collins; Jessy S Deshane; Wayne Cheng; Amy S Weinmann; Hairong Wei; Hongwei Qin; Etty N Benveniste
Journal:  JCI Insight       Date:  2019-04-02

4.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

Review 5.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

6.  Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.

Authors:  Maureen A Mealy; Michael Levy
Journal:  J Neuroimmunol       Date:  2015-08-07       Impact factor: 3.478

7.  Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions.

Authors:  Samira Saadoun; Leslie R Bridges; A S Verkman; Marios C Papadopoulos
Journal:  Neuroreport       Date:  2012-12-19       Impact factor: 1.837

Review 8.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

9.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

Review 10.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.